Xenetic Biosciences (XBIO) news

OFCOM: Decided to focus the remainder of investigation on X's compliance with its illegal content and complaints and reporting duties

The UK's communications regulator, Ofcom, has announced that it will focus the remainder of its investigation on X's compliance with its obligations regarding illegal content and complaints and reporting duties. This decision follows an ongoing review of the platform's adherence to the Online…

CPBIO renewal of continuing connected transactions, notice of special general meeting

Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…

CPBIO renewal of continuing connected transactions, notice of special general meeting

Xenetic Biosciences: Santersus shareholders to own about 85% of combined co post-closing - SEC filing

According to a recent SEC filing, Santersus shareholders will hold approximately 85% of the combined company following the closing of the transaction with Xenetic Biosciences, Inc. Xenetic, a biopharmaceutical company focused on immuno-oncology technologies, is advancing its DNase technology to…

Xenetic Biosciences Inc: Deal expected to create Nasdaq-listed, multi-indication clinical-stage co

Xenetic Biosciences, Inc. (NASDAQ: XBIO) has taken significant steps toward becoming a Nasdaq-listed, multi-indication clinical-stage company. The firm transitioned from the OTCQB to the Nasdaq Capital Market on November 7, 2016, under the ticker symbol “XBIO”. This move was accompanied by a public…